Nektar Therapeutics

company

About

Nektar Therapeutics develops therapeutics based on its advanced polymer conjugate chemistry technology platform.

  • 501 - 1000

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$25M
Industries
Biotechnology,Chemical,Health Care,Therapeutics
Founded date
Jan 1, 1990
Number Of Employee
501 - 1000
Operating Status
Active

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$25M
Nektar Therapeutics has raised a total of $25M in funding over 2 rounds. Their latest funding was raised on Aug 28, 2013 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 28, 2013 Post-IPO Equity $25M 1 AstraZeneca Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Nektar Therapeutics is funded by 1 investors. AstraZeneca are the most recent investors.
Investor Name Lead Investor Funding Round
AstraZeneca Yes Post-IPO Equity